News
Vast Therapeutics Selected to Present at the American Thoracic Society (ATS)2024 Respiratory Innovation Summit
Morrisville, N.C., April 17, 2024 – Vast Therapeutics, a clinical-stage life science company focused on breaking the debilitating cycle of chronic infection and inflammation […]
Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer
Addition of CMO, Medical Director Chris Polage, MD, and enhancements in clinical operations position Company for success in the clinical development of ALX1 in bronchiectasis. […]
Vast Therapeutics Announces Publication of Potential New Treatment for Non-Tuberculosis Mycobacteria Infections
Company targets novel inhaled therapies for drug-resistant chronic airway infections. Morrisville, N.C., January 17, 2024 – Vast Therapeutics announces publication of a manuscript in the journal of Antimicrobial […]
Vast Therapeutics Presents Promising Preclinical Results for Novel Treatment for NTM Disease
Company targets unmet medical need in millions of people around the world with drug resistant chronic airway infections. Durham, N.C., July 1, 2022 – […]
